

















**Figure 5. Inhalers for COPD registered in Singapore**

Relievers – short-acting bronchodilators			
SABA	SAMA	SAMA + SABA	
<b>Salbutamol</b> (Salbuair MDI*, Azmasol MDI*, Ventolin Evohaler MDI, Buventol Easyhaler DPI*) 	<b>Ipratropium</b> (Iprovent MDI*) 	<b>Ipratropium + fenoterol</b> (Berodual N MDI) 	
Maintenance – long-acting bronchodilators			
LAMA			
<b>Umeclidinium</b> (Incruse Ellipta DPI) 	<b>Glycopyrronium</b> (Seebri Breezhaler DPI) 	<b>Tiotropium</b> (Spiriva Respimat SMI) 	
LAMA + LABA			
<b>Umeclidinium + vilanterol</b> (Anoro Ellipta DPI) 	<b>Glycopyrronium + indacaterol</b> (Ultibro Breezhaler DPI) 	<b>Tiotropium + olodaterol</b> (Spiolto Respimat SMI) 	
Maintenance – ICS† combinations			
LABA + ICS			
<b>Formoterol + budesonide</b> (Symbicort Turbuhaler DPI^, Symbicort Rapihaler MDI^, DuoResp Spiromax DPI*) 	<b>Salmeterol + fluticasone propionate</b> (Seretide Accuhaler DPI^, Salfumix Easyhaler DPI^*) 	<b>Vilanterol + fluticasone furoate</b> (Relvar Ellipta DPI^) 	<b>Formoterol + beclomethasone dipropionate</b> (Foster MDI, Foster NEXThaler DPI) 
LAMA + LABA + ICS			
<b>Umeclidinium + vilanterol + fluticasone furoate</b> (Trelegy Ellipta DPI^) 	<b>Glycopyrronium + formoterol + beclomethasone dipropionate</b> (Trimbow MDI) 	<b>Glycopyrronium + formoterol + budesonide</b> (Breztri Aerosphere MDI) 	

**Check if your patient is doubling up on inhalers**

Do not double up on inhalers from the same class of drugs.

For example, if a patient is already on one LAMA such as umeclidinium, do not prescribe another, such as glycopyrronium or tiotropium.

Do not double up on inhalers containing a muscarinic antagonist (SAMA, LAMA, or LAMA + LABA).

This includes a SAMA with LAMA, because of potential antimuscarinic or anticholinergic side effects such as dry mouth and urinary retention.

Do not double up on inhalers containing a LABA (LAMA + LABA, LABA + ICS).

Common side effects include tremors, palpitations, and headaches.

List of inhalers currently registered and available for COPD management in Singapore. Active ingredients in bold denote availability on government subsidy list. Please refer to product inserts for detailed information on the inhalers.

\* Generics.

† ICS (beclomethasone, budesonide, fluticasone) should only be used in combination with LAMA+LABA.

^ Not all strengths available are registered for COPD.

Symbicort Turbuhaler: only 9/320 mcg and 4.5/160 mcg  
 Symbicort Rapihaler: only the 2.25/80 mcg and 4.5/160 mcg

Seretide Accuhaler: only 50/500 mcg  
 Salfumix Easyhaler: only 50/500 mcg

Relvar Ellipta: only 25/100 mcg  
 Trelegy Ellipta: only 100/62.5/25 mcg

DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting beta<sub>2</sub>-agonist; LAMA long-acting muscarinic antagonist; mcg, microgram; MDI, metered dose inhaler; SABA, short-acting beta<sub>2</sub>-agonist; SAMA, short-acting muscarinic antagonist; SMI, soft mist inhaler